New-onset autoimmune diabetes and fatal pathologic pneumatosis after recent durvalumab lung cancer treatment in the United States: a case report

Puntos clave

• This report aims to describe the occurrence of new-onset autoimmune diabetes and fatal pneumatosis following durvalumab treatment.
• Case report detailing patient history and treatment sequence.
• Clinical evaluation of symptoms related to autoimmune diabetes and pneumatosis.
• Pathological examination post-mortem.
• Patient developed autoimmune diabetes shortly after starting durvalumab.
• Fatal pneumatosis was diagnosed post-mortem, linking it to the treatment.
• Highlight concern over potential severe side effects of durvalumab.